阿帕替尼联合TACE治疗原发性肝癌不良反应分析及处理对策

Analysis of the adverse reactions due to the treatment of apatinib combined with TACE for patients suffered from primary liver cancer and the countermeasures

目的分析阿帕替尼联合TACE治疗原发性肝癌的不良反应发生情况,总结临床处理对策。方法选择2016年7月-2019年6月本院收治的60例原发性肺癌患者作为研究对象,进行TACE治疗后,口服小分子靶向药物阿帕替尼,跟踪随访6个月,分别记录患者并发症发生情况,并对并发症进行分类、分级,给予相应处理对策。结果阿帕替尼联合TACE治疗原发性肝癌发生相关并发症主要包括高血压、手足皮肤综合征、乏力、蛋白尿、皮疹、腹泻等发生率分别为43.3%、23.3%、16.7%、6.7%、5%、10%,经积极处理后均可耐受,取得良好效果。结论阿帕替尼联合TACE治疗原发性肝癌虽然有并发症发生,但经积极处理,多数患者均可耐受,具有一定的安全性。

Objective To analyze the occurrence of adverse reactions induced by apatinib combined with TACE in the treatment of 60 patients with primary liver cancer,and summarize the clinical countermeasures.Methods 60 cases of patients suffered with primary liver cancer were treated with TACE and apatinib,and were followed up for 6 months,the complications of them were recorded,the patients were classified according to the occurrence of complications,and given corresponding treatment countermeasures.Results The complications related to apatinib combined with TACE in the treatment of primary liver cancer mainly including hypertensive,hand-foot-skin syndrome,asthenia,proteinuria,erythra,diarrhea,etc.The incidence rate were 43.3%、23.3%、16.7%、6.7%、5%and 10%,respectively.All of the patients were tolerated after active treatment and achieved good results.Conclusions Even there were complications due to apatinib combined with TACE in the treatment of primary liver cancer,most of the patients are tolerable after active treatment,it indicated that the combination of apatinib and TACE is safe on a certain extent.